<DOC>
	<DOCNO>NCT00720434</DOCNO>
	<brief_summary>The purpose study assess potency PF-00868554 , HCV polymerase inhibitor , subject chronically infect HCV evaluate antiviral activity PF-00868554 combination current standard care therapy , pegylated interferon-alpha2a ( PEGASYS ) ribavirin ( COPEGUS ) .</brief_summary>
	<brief_title>A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Treatment naive ( prior treatment IFNa +/ RBV regimens . Subjects discontinue IFNa contain regimen &lt; 2 week therapy due tolerability issue consider treatment naive . HCV RNA &gt; 100,000 IU/mL screening . Genotype 1 . A diagnosis chronic HCV infection least 6 month . Evidence acute chronic infection HIV HBV . Exposure within previous three month investigational antiHCV agent . Evidence severe decompensated liver disease . Subjects liver disease unrelated HCV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>